F. mortiferum Bacteremia in a Pediatric Patient with B-cell Acute Lymphoblastic Leukemia; A Rare Case from Pakistan

Authors

  • Suman Ahuja Indus Hospital & Health Network, Karachi Pakistan
  • Moiz Khan Indus Hospital & Health Network, Karachi Pakistan

DOI:

https://doi.org/10.55629/pakjpathol.v36i1.877

Abstract

INTRODUCTION: Fusobacterium species infect individuals who are immunocompromised, often due to chronic disease and chemotherapy, and have been rarely associated with bloodstream infections (BSI). Among the species of the genus, F. mortiferum has been rarely reported in the literature. Herein, we report a rare case of F. mortiferum bacteremia in a pediatric patient with B-cell Acute Lymphoblastic Leukemia (B-ALL).

METHODS: A four-year-old-female patient known case of B-ALL and on chemotherapy, presented with complaints of fever without rigors and chills, sore throat and dry cough since five days and nasal bleeding since two days. On examination, patient was lethargic with a temperature of 103oF. Throat was hyperemic on oral examination. Two sets of blood cultures were sent to the microbiology laboratory for evaluation of bacteremia.

RESULTS: Blood cultures revealed bacterial growth after 72 hours on anaerobic incubation. Gram stain from the blood culture broth showed pleomorphic gram-negative rods. Subculture on 5% Sheep Blood Agar grew pin-pointed, grey, convex, translucent and non-hemolytic colonies. The isolate was identified as F. mortiferum on VITEK-2 automated system (BioMérieux) and was sensitive to clindamycin, metronidazole, amoxicillin/clavulanate, piperacillin/tazobactam, imipenem and meropenem via Disk Diffusion method.

CONCLUSION: We reported a rare case of F. mortiferum BSI in a pediatric patient B-ALL, which according to the best of our knowledge is the first case of F. mortiferum infection from Pakistan. The patient was successfully treated with metronidazole with complete resolution of symptoms after three weeks of therapy. In this regard, it is crucial to report similar cases as prompt reporting and antibiotic therapy are essential for the appropriate management of such patients.

References

Fujiwara N, Kitamura N, Yoshida K, Yamamoto T, Ozaki K, Kudo Y. Involvement of Fusobacterium species in oral cancer progression: A literature review including other types of cancer. Int J Mol Sci. 2020; 21(17): 6207. DOI: http://dx.doi.org/10.3390/ijms21176207

Almohaya AM, Almutairy TS, Alqahtani A, Binkhamis K, Almajid FM. Fusobacterium bloodstream infections: A literature review and hospital-based case series. Anaerobe. 2020; 62(102165): 102165. DOI: http://dx.doi.org/10.1016/j.anaerobe.2020.102165

Perinkulam Sathyanarayanan S, Hamid K, Hoerschgen K, Oliver T. A rare case of rectal bleeding and Fusobacterium mortiferum sepsis due to solitary fibrous tumour originating from the mesentery. BMJ Case Rep. 2021;14(10): e244603. DOI: http://dx.doi.org/10.1136/bcr-2021-244603

Stavreas NP, Amanatidou CD, Hatzimanolis EG, Legakis I, Naoum G, Lakka-Papadodima E, et al. Thyroid abscess due to a mixed anaerobic infection with Fusobacterium mortiferum. J Clin Microbiol. 2005; 43(12): 6202–4. DOI: http://dx.doi.org/10.1128/jcm.43.12.6202-620 4.2005

ESCMID-European Society of Clinical Microbiology. Infectious diseases. EUCAST: clinical breakpoints and dosing of antibiotics. Eucast.org. 2024. Available from: https://www.euc ast.org/clinicalbreakpoints

Prout J, Glymph R. Anaerobic septicemia secondary to fusobacterium mortiferum. J Natl Med Assoc 1986; 78: 337.

Available from: https://pmc.ncbi.nlm.nih.gov/ articles/PMC2571289/pdf/jnma00255-0084.pdf

Appelbaum PC, Spangler SK, Jacobs MR. Lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. Centers. Antimicrob Agents Chemother. 1990; 34: 1546–9. DOI: https://doi.org/10.1128/aac.34.8.1546

Dahlgren D, Lennernäs H. Review on the effect of chemotherapy on the intestinal barrier: Epithelial permeability, mucus and bacterial translocation. Biomed Pharmacother. 2023; 162(114644): 114644. DOI: http://dx.doi.org/10.1016/j.biopha.2023.114644

Downloads

Published

20-03-2025

How to Cite

1.
Ahuja S, Khan M. F. mortiferum Bacteremia in a Pediatric Patient with B-cell Acute Lymphoblastic Leukemia; A Rare Case from Pakistan . Pak J Pathol [Internet]. 2025 Mar. 20 [cited 2026 Nov. 17];36(1):59-62. Available from: https://www.pakjpath.com/index.php/Pak-J-Pathol/article/view/877